Toronto Dominion Bank
DNLI icon

Toronto Dominion Bank’s Denali Therapeutics DNLI Stock Holding History

Toronto Dominion Bank’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$58 – 1544
2024
Q3 		$58 Hold
2
– – ﹤0.01% 1135
2024
Q2 		$46 Hold
2
– – ﹤0.01% 1400
2024
Q1 		$41 Hold
2
– – ﹤0.01% 1375
2023
Q4 		$43 Hold
2
– – ﹤0.01% 1521
2023
Q3 		$41 Hold
2
– – ﹤0.01% 1754
2023
Q2 		$0 Hold
2
– – ﹤0.01% 1552
2023
Q1 		$0 Buy
+2
New +$55 ﹤0.01% 1496
2022
Q4 		– Sell
-42,650
Closed -$1.31M – 1526
2022
Q3 		$1.31M Buy
42,650
+42,648
+2,132,400% +$1.39M ﹤0.01% 1012
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1452
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1548
2021
Q4 		$0 Buy
+2
New +$95 ﹤0.01% 1610
2019
Q4 		– Sell
-43
Closed -$1K – 1394
2019
Q3 		$1K Sell
43
-17
-28% -$325 ﹤0.01% 1400
2019
Q2 		$1K Buy
+60
New +$1.34K ﹤0.01% 1370

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank's DNLI Position: Q4 2024 in Review

Toronto Dominion Bank sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 2 shares — an estimated $58 sold.

Toronto Dominion Bank first reported a position in DNLI in Q2 2019 and held it in 13 quarters. The position peaked at $1.31M in Q3 2022. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • Toronto Dominion Bank reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Toronto Dominion Bank sold 2 Denali Therapeutics shares in Q4 2024, an estimated $58.
  • Toronto Dominion Bank first reported a position in Denali Therapeutics in Q2 2019 and held it in 13 quarters.
  • Toronto Dominion Bank's Denali Therapeutics position peaked at $1.31M in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Toronto Dominion Bank's 13F filing for Q4 2024, filed 14 Feb 2025.